Latest News

Feb 14, 2017

Propanc Successfully Completes Low Dose Group for GLP-Compliant 28-Day Repeat-Dose Toxicity Study

In-Life Phase for Middle and High Dose Groups Set to Commence Immediately MELBOURNE, AUSTRALIA -- (Marketwired) -- 02/14/17 -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the…

View All Press Releases